Journal
EPILEPSIA
Volume 57, Issue 2, Pages 222-232Publisher
WILEY-BLACKWELL
DOI: 10.1111/epi.13270
Keywords
GABA; NKCC1; Pharmacoresistance; Epilepsy; Chloride; Status epilepticus; Epilepsy
Categories
Funding
- Epilepsy Foundation
- Academy of Finland
- [NS073574]
Ask authors/readers for more resources
ObjectiveWe investigated the role of chloride homeostasis in seizure progression and development of pharmacoresistant status epilepticus (SE) by pharmacologically targeting the Na-K-Cl cotransporter (NKCC1) with bumetanide. We also investigated the ability of bumetanide to restore the efficacy of diazepam following SE. MethodsKainic acid (KA)-induced SE in vivo and 0-Mg2+-induced seizure-like events (SLEs) in vitro were monitored using electroencephalography (EEG) recordings in freely moving adult male mice and extracellular field potential recordings in acute entorhinal cortex-hippocampus slices, respectively. The ability of bumetanide to decrease epileptiform activity and prevent the development of pharmacoresistance to diazepam following SE was evaluated. ResultsBumetanide treatment significantly reduced KA-induced ictal activity in vivo and SLEs in vitro. In addition, bumetanide restored the efficacy of diazepam in decreasing ictal activity following SE in both the in vivo and in vitro models. SignificanceOur data demonstrate an anticonvulsant effect of bumetanide on KA-induced seizures in adult mice, suggesting a role for chloride plasticity in seizure progression. These data also demonstrate that the erosion of inhibition during seizure progression could underlie the development of pharmacoresistant SE and implicate a role for chloride plasticity in this process.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available